Abstract
Technetium-99m tetrofosmin, a lipophilic cationic complex molecule, was introduced for myocardial imaging. In some biodistribution studies it has also been reported to accumulate in the thyroid gland. Our objectives were to determine which thyroid nodules retain tetrofosmin and whether preoperative evaluation of malignancy is possible. Tetrofosmin scintigraphy was performed in 57 patients with a cold thyroid nodule on previously performed pertechnetate scintigraphy. All patients had undergone ultrasonography and sonographically guided fine-needle aspiration biopsy. The tetrofosmin scintigrams were obtained 5 min (early image) and 1 h (late image) after intravenous injection of 370 MBq. Only nodules that showed clear tracer retention after 1 h in comparison with retention at 5 min were classified as TETRO positive. Nodules without late retention were classified as TETRO negative. All patients underwent surgery and the histological results were compared with the results of tetrofosmin scintigraphy. Ten out of 11 patients with thyroid carcinoma (two pT1, three pT2, five pT4) were TETRO negative. One patient with papillary carcinoma (pT2) was TETRO positive. The mean nodular to thyroid tissue (N/T) ratio for the late scan was 1.0±0.20. There were 21 patients with thyroid adenomas (seven follicular, seven microfollicular and seven oxyphilic); 15 of these patients were TETRO positive and six TETRO negative. The mean N/T ratio for the late images was 1.34±0.41. All patients with degenerative goitre (24 cases) and the one patient with Hashimoto's disease were TETRO negative after 1 h and the N/T ratio was 0.92±0.12 on the late scan. Our results indicate that99mTc-tetrofosmin scanning is of little value preoperatively in distinguishing thyroid carcinoma from other thyroid nodules. Tetrofosmin tends to demonstrate thyroid adenomas but does not have a routine role in the assessment of thyroid nodules.
Similar content being viewed by others
References
Higley B, Smith F, Smith T, et al. Technetium-99m-1,2-bis [bis(2-ethoxyethyl)phospino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent.J Nucl Med 1993; 34: 30–38.
Nèmec J, Nyvltova O, Preiningerova M, et al. Positive thyroid cancer scintigraphy using Tc-99m-tetrofosmin (Myoview): a preliminary report.Nucl Med Commun 1995; 16: 694–697.
Kosuda S, Yokoyama H, Katayama M, et. al. Technetium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma.J Nucl Med 1995; 22: 1218–1220.
Klain M, Maurea S, Lastoria S, et al. Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer.J Nucl Med 1995; 36: 2248–2251
Aigner RM, Füger GF, Nicoletti R, et al. Parathyroid scintigraphy: comparison of technetium-99m methoxyisobutylisonitrile and technetium-99m tetrofosmin studies.Eur J Nucl Med 1996; 23: 693–696.
Gallowitsch HJ, Fellinger J, Kresnik E, Lind P. Preoperative scintigraphic and intraoperative scintimetric localization of parathyroid adenoma with cationic Tc-99m complexes and a hand-held-gamma-probe.Nuklearmedizin 1997; 36: 13–18.
Harada T, Ito Y, Shimaoka K, et al. Clinical evaluation of 201thallium-chloride scan for thyroid nodule.Eur J Nucl Med 1980; 5: 125–130.
Hoefnagel CA, Delprat CC, Marcuse HR, et al. Role of thallium-201 total body scintigraphy in follow-up of thyroid carcinoma.J Nucl Med 1986; 27: 1854–1857.
Klain M, Maurea S, Cuocolo A, et al. Technetium-99m tetrofosmin imaging in thyroid diseases: comparison with Tc99m-pertechnetate, thallium-201 and Tc-99m-methoxyisobutylisonitrile scans.Eur J Nucl Med 1996; 23: 1568–1574.
Norusis MJ. SPSS for Windows. Advanced statistics Release 6.0. Chicago: SPSS Inc 1993, 31–56.
McBiles M, Lambert A, Cote M, et al. Sestamibi parathyroid imaging.Semin Nucl Med 1995: 3: 221–234.
Coakley AJ, Kettle AG, Wells CP, et al. Tc-99m Sestamibi - a new agent for parathyroid imaging.Nucl Med Commun 1989; 10: 791–794.
Briele B, Hotze A, Kropp J, et al. Vergleich von 201-T1 und 99m-Tc-MIBI in der Nachsorge des differenzierten Schilddrüsenkarzinoms.Nuklearmedizin 1991; 30: 115–124
Lebouthillier G, Morais J, Picard M, et al. Tc-99m sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid.Clin Nucl Med 1993; 18: 657–661.
Kresnik E, Gallowitsch HJ, Mikosch P, Lind P. 99m Tc-MIBI scintigraphy of thyroid nodules in an endemic goiter area.J Nucl Med 1997; 38: 62–65.
Lind P, Gallowitsch HJ, Langsteger W, et al. Technetium-99m tetrofosmin whole body scintigraphy in the follow up to differentiated thyroid carcinoma.J Nucl Med 1997; 38: 348–352.
Gallowitsch HJ, Kresnik E, Mikosch P, Lind P, Tc-99m tetrofosmin scintigraphy: An alternative scintigraphic method for following-up differentiated thyroid carcinoma. Preliminary results.Nuklearmedizin 1996; 35: 230–235.
Songadele JA, Younes A, Maublant J et al. Uptake of Tc-99m-tetrofosmin in isolated mitochondria: evidence for an active mechanism [abstract].J Nucl Med 1994; 35: 46P-47P.
Földes I, Lévay A, Stotz G. Comparative scanning of thyroid nodules with technetium-99m-pertechnetate and technetium-99m methoxyisobutylisonitrile.Eur J Nucl Med 1993; 20: 330–331.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kresnik, E., Gallowitsch, HJ., Mikosch, P. et al. Evaluation of thyroid nodules with technetium-99m tetrofosmin dual-phase scintigraphy. Eur J Nucl Med 24, 716–721 (1997). https://doi.org/10.1007/BF00879657
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00879657